These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18088548)

  • 21. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency.
    Micheloud D; Berenguer J; Bellón JM; Miralles P; Cosin J; de Quiros JC; Conde MS; Muñoz-Fernández MA; Resino S
    J Infect; 2008 Feb; 56(2):130-6. PubMed ID: 18192020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
    Benito JM; López M; Lozano S; González-Lahoz J; Soriano V
    J Infect Dis; 2008 Nov; 198(10):1466-73. PubMed ID: 18847371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
    Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI
    J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dyspepsia in HIV-infected patients under highly active antiretroviral therapy.
    Werneck-Silva AL; Prado IB
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1712-6. PubMed ID: 17559368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort).
    Gardette V; Bongard V; Dallongeville J; Arveiler D; Bingham A; Ruidavets JB; Amouyel P; Haas B; Ducimetière P; Ferrières J
    Am J Cardiol; 2009 Feb; 103(3):381-6. PubMed ID: 19166693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.
    Molina-Pinelo S; Vallejo A; Díaz L; Soriano-Sarabia N; Ferrando-Martínez S; Resino S; Muñoz-Fernández MA; Leal M
    J Antimicrob Chemother; 2009 Sep; 64(3):579-88. PubMed ID: 19608579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART).
    Lapphra K; Vanprapar N; Phongsamart W; Chearskul P; Chokephaibulkit K
    J Med Assoc Thai; 2005 Jul; 88(7):956-66. PubMed ID: 16241026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of treatment and immunological recovery on tuberculosis relapses in HIV-infected patients.
    Lopez-Cortes LF; Marin-Niebla A; Lopez-Cortes LE; Villanego I; Rodriguez-Diez M; Pascual-Carrasco R
    Int J Tuberc Lung Dis; 2005 Dec; 9(12):1385-90. PubMed ID: 16466062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
    Roux P; Carrieri MP; Cohen J; Ravaux I; Poizot-Martin I; Dellamonica P; Spire B
    Clin Infect Dis; 2009 Nov; 49(9):1433-40. PubMed ID: 19807275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.
    Gazzola L; Tincati C; Bellistrì GM; Monforte Ad; Marchetti G
    Clin Infect Dis; 2009 Feb; 48(3):328-37. PubMed ID: 19123868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV infection and advanced age emerging epidemiological, clinical, and management issues.
    Manfredi R
    Ageing Res Rev; 2004 Jan; 3(1):31-54. PubMed ID: 15164725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection.
    Tincati C; Biasin M; Bandera A; Violin M; Marchetti G; Piacentini L; Vago GL; Balotta C; Moroni M; Franzetti F; Clerici M; Gori A
    Antivir Ther; 2009; 14(3):321-30. PubMed ID: 19474466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand.
    Chaiwarith R; Wachirakaphan C; Kotarathititum W; Praparatanaphan J; Sirisanthana T; Supparatpinyo K
    Int J Infect Dis; 2007 Sep; 11(5):413-6. PubMed ID: 17331776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4 count and viral load time-courses in patients treated with highly active antiretroviral therapy and association with the CDC staging system.
    Collazos J; Knobel H; Casado JL;
    HIV Med; 2006 Nov; 7(8):504-13. PubMed ID: 17105509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.